Keeping patients engaged and informed is paramount to the success of a DCT, but each step in the clinical trial journey creates friction that can cause an otherwise interested patient to drop out or drop off. Fortunately, technology platforms are evolving to provide patients a sense of ease that builds confidence in participation.
Listen in as industry leaders discuss how to execute successful DCTs by building a seamless patient experience from enrollment to trial completion.
Keeping patients engaged and informed is paramount to the success of a DCT, but each step in the clinical trial journey creates friction that can cause an otherwise interested patient to drop out or drop off. Fortunately, technology platforms are evolving to provide patients a sense of ease that builds confidence in participation.
Listen in as industry leaders discuss how to execute successful DCTs by building a seamless patient experience from enrollment to trial completion.
Keeping patients engaged and informed is paramount to the success of a DCT, but each step in the clinical trial journey creates friction that can cause an otherwise interested patient to drop out or drop off. Fortunately, technology platforms are evolving to provide patients a sense of ease that builds confidence in participation.
Listen in as industry leaders discuss how to execute successful DCTs by building a seamless patient experience from enrollment to trial completion.
Keeping patients engaged and informed is paramount to the success of a DCT, but each step in the clinical trial journey creates friction that can cause an otherwise interested patient to drop out or drop off. Fortunately, technology platforms are evolving to provide patients a sense of ease that builds confidence in participation.
Listen in as industry leaders discuss how to execute successful DCTs by building a seamless patient experience from enrollment to trial completion.
Keeping patients engaged and informed is paramount to the success of a DCT, but each step in the clinical trial journey creates friction that can cause an otherwise interested patient to drop out or drop off. Fortunately, technology platforms are evolving to provide patients a sense of ease that builds confidence in participation.
Listen in as industry leaders discuss how to execute successful DCTs by building a seamless patient experience from enrollment to trial completion.
Keeping patients engaged and informed is paramount to the success of a DCT, but each step in the clinical trial journey creates friction that can cause an otherwise interested patient to drop out or drop off. Fortunately, technology platforms are evolving to provide patients a sense of ease that builds confidence in participation.
Listen in as industry leaders discuss how to execute successful DCTs by building a seamless patient experience from enrollment to trial completion.
Keeping patients engaged and informed is paramount to the success of a DCT, but each step in the clinical trial journey creates friction that can cause an otherwise interested patient to drop out or drop off. Fortunately, technology platforms are evolving to provide patients a sense of ease that builds confidence in participation.
Listen in as industry leaders discuss how to execute successful DCTs by building a seamless patient experience from enrollment to trial completion.
ObvioHealth recently completed the first-ever fully virtual urogynecology study to evaluate a medical digital intravaginal device for female stress urinary incontinence. In this randomized trial, pelvic floor muscle contractions were monitored.
How do increasingly prevalent DCT methods fit into the existing clinical trial ecosystem? In short: There are complexities. Many eClinical platforms still lack key capabilities, which often require complex integrations with third-party solutions.
Leveraging real-world examples from the first fully virtual clinical trial in the urogynecology space, our presenters discuss the ways in which digital solutions have helped to increase patient recruitment, engagement, and completion rates.